Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology.
Researchers have discovered a natural mechanism that can help prevent the formation of harmful protein clumps that contribute to the development of amyotrophic lateral sclerosis (ALS), according to results of ... Read more
Massachusetts General Hospital in Boston and California Pacific Medical Center in San Francisco will be among the sites where ALS patients will take in a Phase 3 clinical trial of BrainStorm Cell ... Read more
A musical instrument that can be played only with brain activity may empower and rehabilitate patients with ALS and other motor diseases. Invoking brain scans known as electroencephalograms, University of ... Read more
Neuraltus Pharmaceuticals has completed enrollment its Phase 2 confirmatory study of NP001 (NCT02794857) in ALS patients with systemic inflammation. The company expects the last patient in the trial to ... Read more
The former malaria therapy pyrimethamine reduces levels of an ALS-linked protein in the spinal fluid of patients whose disease stems from gene mutations, a Phase 1/2 clinical trial shows. ... Read more
Mallinckrodt has launched the Phase 2b PENNANT trial (NCT03068754) to investigate the safety and effectiveness of H.P. Acthar Gel (repository corticotropin injection) as a treatment for amyotrophic lateral sclerosis ... Read more
ProMIS Neurosciences hopes to develop an ALS therapy around a component of a protein that is faulty in the disease. The TDP43 protein’s abnormality leads to it becoming misfolded — that is, ... Read more